Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis
Latest Information Update: 04 Aug 2026
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms CIMcare
- Sponsors UCB Biopharma
Most Recent Events
- 31 Jul 2026 Status changed from active, no longer recruiting to completed.
- 01 Apr 2026 Planned End Date changed from 15 Aug 2034 to 2 Jul 2026.
- 01 Apr 2026 Planned primary completion date changed from 19 Sep 2029 to 9 Apr 2026.